Sound fundamentals, growth prospects and reasonable valuation make it an acceptable offer

Creating a `value-perception’ and selling that `dream’ at a huge profit is the new paradigm invented by start-ups floated by professional-founders! When will Sebi wake up from its slumber to stop this `trading of losses’ by the scheming fatherless-motherless start-ups?

Boom-time valuation and promoter’s negative cost of holding make the offer a risky proposition.

Absurd valuation of a predominantly trading company whose bottom line turned black only on the eve of public issue and accumulated deficit is twice the equity capital defies all logic of issue pricing

Optimal pricing during equity market boom is bound to impact the stock price severely when the market takes a turn

Stagnant revenue and receding bottom line in the face of bulging equity coupled with optimum pricing leaves little room for capital appreciation

Striking effortlessly when the iron is hot!

IPO chemistry changes drastically as market mood swings!

Listed group company Medinova Diagnostic’s contrasting track reveals promoter’s intent!

Core promoter’s unassuming stake, lack of succession plan, steep IPO-pricing and post-pandemic court rulings weigh against the scrip